FIRST AMENDMENT TO EXCHANGE AND REGISTRATION RIGHTS AGREEMENTExchange and Registration Rights Agreement • October 2nd, 2020 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This FIRST AMENDMENT TO EXCHANGE AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is entered into as of September 28, 2020 by and between Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), and Fortis Advisors LLC, a Delaware limited liability company in its capacity as the Equityholders’ Representative (the “Equityholders’ Representative”), and amends that certain Exchange and Registration Rights Agreement entered into by and among the Company and the Equityholders, dated as of March 18, 2019 (the “Exchange Agreement”). The Company and the Equityholders’ Representative are referred to herein collectively as the Parties, and, individually as a “Party.” Unless otherwise defined herein, capitalized terms used in this Amendment have the meanings ascribed to them in the Exchange Agreement.
